menu
    • menu
    [{"orgOrder":0,"company":"SciTech Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Undisclosed"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Storm Lake Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Storm Lake Capital","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Storm Lake Capital"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Undisclosed"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Undisclosed"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Undisclosed"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"SciTech Development \/ Undisclosed"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciTech Development \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Undisclosed"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Financing","leadProduct":"Fenretinide","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by SciTech Development

    Menu

    SciTech Development

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $5.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Scitech Development Closes $5.5M Funding for Cancer Trials

                            Details : The financing will support the development of ST-001 (fenretinide), which is being evaluated for T-cell Non-Hodgkin Lymphoma.

                            Product Name : ST-001

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            September 24, 2025

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $5.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

                            Details : Fenretinide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide

                            Details : ST-001 (nanofenretinide) works by inhibiting the growth of cancer cell, currently it is being investiated for T-cell non-Hodgkin lymphoma and for small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2025

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SCITECH Shows Promising Phase 1a Results for T-Cell Non-Hodgkin Lymphoma

                            Details : ST-001 (fenretinide), is currently undergoing trials in IV infusion form for treating patients with T-cell non-Hodgkin's lymphoma, including Peripheral T-cell Lymphoma and Sezary Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Storm Lake Capital

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            SciTech Development Raises Additional $3.2M to Expand Clinical Trials for Cancer

                            Details : The financing will be used to advance the company's Phase 1b clinical trials of ST-001 (nanofenretinide) for T-cell non-Hodgkin lymphoma and subsequent clinical trials for small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 04, 2024

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Storm Lake Capital

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001

                            Details : SciTech's primary drug candidate, ST-001 (fenretinide), is currently undergoing Phase I clinical trials in IV infusion form for treating patients with T-cell non-Hodgkin's lymphoma, including Peripheral T-cell Lymphoma and Sezary Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 20, 2023

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SciTech Development, LLC Submits COVID-19 Treatment with Proven Antiviral Activity to U.S. Health & Human Serv...

                            Details : Fenretinide has demonstrated preclinical in-vitro antiviral activity against a number of viruses including MERs, Dengue, Zika, West Nile, HIV, and HCV.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2020

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciTech Development

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

                            Details : Fenretinide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 21, 2020

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth